Sale!

DOCK7 Gene Early Infantile Epileptic Encephalopathy Type 23 Genetic Test

Original price was: $700.Current price is: $500.

-29%

The DOCK7 Gene Early Infantile Epileptic Encephalopathy Type 23 NGS Genetic DNA Test is a comprehensive diagnostic tool that identifies mutations in the DOCK7 gene responsible for severe neurological conditions in infants. Using advanced next-generation sequencing technology, this test provides precise detection of genetic variants associated with developmental delays, treatment-resistant seizures, and epileptic encephalopathy. Early diagnosis through this $500 USD test enables targeted treatment strategies, genetic counseling, and family planning guidance. The test is particularly crucial for infants exhibiting unexplained seizures, developmental regression, or abnormal EEG patterns. Results are typically available within 3-4 weeks, providing families with critical information for managing this rare neurological disorder.

Trusted Testing. Expert Care. Guaranteed Privacy.

  • Accredited and Trusted
  • Expert Scientists, Advanced Technology
  • Data Privacy Guaranteed
Guaranteed Safe Checkout

DOCK7 Gene Early Infantile Epileptic Encephalopathy Type 23 NGS Genetic DNA Test

Understanding DOCK7 Gene-Related Neurological Disorders

The DOCK7 Gene Early Infantile Epileptic Encephalopathy Type 23 NGS Genetic DNA Test represents a breakthrough in pediatric neurological diagnostics. This comprehensive genetic analysis focuses on identifying mutations in the DOCK7 gene, which plays a critical role in brain development and neuronal function. Early infantile epileptic encephalopathy type 23 is a severe neurological condition characterized by treatment-resistant seizures that typically begin within the first months of life, often leading to significant developmental delays and neurological impairment.

What This Advanced Genetic Test Detects

Our state-of-the-art next-generation sequencing (NGS) technology precisely identifies pathogenic variants in the DOCK7 gene, including:

  • Point mutations and single nucleotide variants
  • Small insertions and deletions (indels)
  • Copy number variations affecting the DOCK7 gene region
  • Complex structural rearrangements
  • Novel mutations previously undetected by conventional methods

Clinical Indications: Who Should Consider This Test?

This specialized genetic test is recommended for infants and young children presenting with:

  • Early-onset seizures within the first 6 months of life
  • Developmental regression or stagnation
  • Abnormal electroencephalogram (EEG) patterns
  • Treatment-resistant epilepsy
  • Hypotonia (reduced muscle tone)
  • Microcephaly or abnormal head growth
  • Family history of similar neurological conditions
  • Unexplained developmental delays with seizure activity

Critical Benefits of Early Genetic Diagnosis

Obtaining a precise genetic diagnosis through this test provides numerous advantages:

  • Targeted Treatment Planning: Enables neurologists to develop personalized treatment strategies
  • Prognostic Information: Helps families understand the expected disease course
  • Genetic Counseling: Provides essential information for family planning decisions
  • Early Intervention: Facilitates timely access to specialized therapies and support services
  • Research Opportunities: Connects families with clinical trials and emerging treatments
  • Reduced Diagnostic Odyssey: Minimizes unnecessary testing and medical procedures

Understanding Your Test Results

Our comprehensive genetic counseling team provides detailed interpretation of your results:

  • Positive Result: Indicates a pathogenic mutation in the DOCK7 gene, confirming the diagnosis of early infantile epileptic encephalopathy type 23
  • Negative Result: Suggests that DOCK7 mutations are not the cause of the symptoms, guiding further diagnostic evaluation
  • Variant of Uncertain Significance: Identifies genetic changes requiring additional research and family studies
  • Carrier Status: Provides information about inheritance patterns and recurrence risks

Test Specifications and Pricing

Test Component Details Price (USD)
Test Name DOCK7 Gene Early Infantile Epileptic Encephalopathy Type 23 NGS Genetic DNA Test
Discount Price Limited Time Offer $500
Regular Price Standard Rate $700
Turnaround Time Comprehensive Analysis 3-4 Weeks
Sample Type Blood, Extracted DNA, or Blood on FTA Card
Testing Method Next-Generation Sequencing (NGS)

Nationwide Accessibility and Support

We maintain comprehensive testing facilities across the United States, with specialized centers in:

  • New York City and surrounding metropolitan areas
  • Los Angeles and Southern California regions
  • Chicago and Midwest locations
  • Houston and Texas medical centers
  • Phoenix and Southwest facilities
  • All major metropolitan areas nationwide

Pre-Test Preparation and Requirements

To ensure optimal testing outcomes, we recommend:

  • Comprehensive clinical history documentation
  • Genetic counseling session to create detailed family pedigree
  • Neurological evaluation and EEG results when available
  • Discussion of testing implications with our genetic specialists

Take the Next Step Toward Diagnosis

Don’t let uncertainty about your child’s neurological symptoms continue. Early diagnosis of DOCK7-related disorders can significantly impact treatment outcomes and quality of life. Our team of board-certified geneticists and neurologists is ready to provide the answers your family deserves.

Call or WhatsApp us today at +1(267) 388-9828 to schedule your genetic testing consultation and take the first step toward understanding your child’s condition.

Our dedicated patient coordinators are available to discuss insurance coverage, payment options, and scheduling at our convenient locations throughout the United States. With our current promotional pricing of $500 USD (regularly $700), there’s never been a better time to pursue definitive genetic answers for your child’s neurological health.